Physician profile
Tena E Murphy
NPI 1821009341
$1,304.49
in general payments reported to CMS, 2019-2025
15 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $68.58 · 2021: $83.93 · 2022: $125 · 2023: $257 · 2024: $133 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $579.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $578.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $736.39 | 2019-2025 | |
| United Therapeutics Corporation | $94.66 | 2022-2025 | Tyvaso, Tyvaso |
| Sanofi-Aventis U.S. LLC | $92.55 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $66.45 | 2022-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.95 | 2020-2024 | Jardiance |
| Boston Scientific Corporation | $49.64 | 2019-2023 | Watchman Access System |
| Amgen INC. | $43.82 | 2019-2023 | Repatha |
| Janssen Pharmaceuticals, INC | $33.14 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $31.23 | 2019-2024 | Wainua |
| Alnylam Pharmaceuticals INC. | $17.49 | 2022 | |
| Scpharmaceuticals INC. | $17.42 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.77 | 2023 | Lifevest |
| Novo Nordisk INC | $14.04 | 2023 | Rybelsus, Ozempic |
| Lexicon Pharmaceuticals, INC. | $13.52 | 2023 | Inpefa |
| Pfizer INC. | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tena Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.